RE:AstraZeneca's ADC disappoints - on severe adverse eventsJuly 11, 2023, ADC Therapeutics pauses ADC Zynlonta Phase II trial enrollment on reported seven patient deaths, 5 serious adverse events.
ADC Therapeutics reported today that it was stopping enrollment in a study of Zynlonta after seven patients with diffuse large B cell lymphoma died from respiratory problems following treatment.
https://endpts.com/adc-therapeutics-pauses-zynlonta-trial-enrollment-after-7-patient-deaths/
Pfizer had planned on the US$43 Billion acquisition of anti-body drug conjugate company Seagen, which would likely be overturned on the FTC's recent actions involving anti-trust/anti-competitive scrutiny like that made against the Amgen-Horizon merger.